Trial
NCT03708003
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Swiss Cancer Institute
Collaborators
—
Condition
Relapsed/Refractory Chronic Lymphocytic Leukemia
Intervention
Ibrutinib
Why stopped
The board decision has been made to conclude the trial ahead of schedule. The primary endpoint has been successfully achieved and published, and funding was secured to support these three years of followup.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-30